Logo

HKPD

Hong Kong Pharma Digital Technology Holdings Limited

HKPD

Hong Kong Pharma Digital Technology Holdings Limited • NASDAQ
$0.99 ▲ 2.89% (+0.03)
Market Cap $10.86 M
52w High $3.79
52w Low $0.81
Dividend Yield 0%
P/E 5.81
Volume 38.66K
Outstanding Shares 11.00M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $9.223M ▼ $1.405M ▲ $-855.616K ▼ -9.277% ▼ $-0.082 ▼ $-793.324K ▼
Q2-2025 $11.091M ▲ $878.568K ▼ $828.56K ▼ 7.47% ▼ $0.083 ▼ $1.059M ▼
Q4-2024 $9.679M ▲ $923.234K ▼ $1.081M ▲ 11.165% ▲ $0.108 ▲ $1.362M ▲
Q2-2024 $7.009M $1.027M $249.036K 3.553% $0.036 $371.062K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $3.006M ▲ $9.417M ▼ $4.428M ▼ $4.99M ▼
Q2-2025 $364.99K ▼ $10.162M ▲ $4.81M ▲ $5.352M ▲
Q4-2024 $619.575K $8.667M $4.414M $4.254M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-855.616K ▼ $-183.906K ▼ $-2.349M ▼ $2.907M ▲ $0 $-212.784K ▼
Q2-2025 $828.56K ▼ $753.12K ▲ $-106.344K ▼ $-912.024K ▼ $0 $712.084K ▲
Q4-2024 $1.081M ▲ $-310.412K ▼ $209.858K ▲ $475.774K ▲ $0 ▼ $-311.418K ▼
Q2-2024 $249.036K $-83.918K $-250.654K $61.542K $252.776K $-135.648K

Five-Year Company Overview

Income Statement

Income Statement The income statement is very light, showing only a tiny level of revenue and essentially no meaningful profit or operating activity yet. This looks more like a shell or transition-stage company than an established logistics or biotech operator. Past earnings per share jump around in a way that likely reflects SPAC and listing-related accounting rather than the strength of an underlying business. Overall, the historical income profile does not yet tell a clear story of a mature, scalable business model, either in logistics or biotech.

Balance Sheet

Balance Sheet The balance sheet is also very small, with limited assets and no visible build-up of cash or debt. This suggests the company is still in an early or transitional phase and has not yet deployed large amounts of capital into physical infrastructure, labs, or large logistics networks. With equity also minimal, the company appears financially “thin,” which means future growth will likely require fresh capital, partnerships, or both. In short, the balance sheet does not yet reflect the scale you would expect from either a major logistics player or a fully funded biotech platform.

Cash Flow

Cash Flow Cash flow data show almost no activity from operations, investing, or capital spending. That fits with a business that has not yet ramped up either its logistics or biotech ambitions in a substantial way. There is no visible track record of generating cash from day‑to‑day operations, nor of sustained investment into new assets or research. Future cash flows will likely depend heavily on how the strategic pivot to biotechnology is funded and executed.

Competitive Edge

Competitive Edge In its current form, the company has a niche position in cross‑border pharmaceutical e‑commerce logistics between Hong Kong and Mainland China. Its strengths are practical: integrated supply‑chain systems, a specialized warehousing and ERP platform, use of digital tools, and know‑how in dealing with pharma regulations and customs. A partnership with a major Chinese e‑commerce platform adds credibility and network access. However, the planned pivot into biotechnology radically changes the competitive playing field, moving the company from an operational logistics niche into a crowded, science‑driven arena dominated by established global and regional biotech firms. The existing logistics moat may not automatically translate into an edge in biotech.

Innovation and R&D

Innovation and R&D Historically, the company’s “innovation” has been about using software, ERP systems, and some AI‑driven tools to streamline pharma logistics and compliance. This is useful, but more process‑oriented than breakthrough science. The planned transition to Cellyan Biotechnology would shift the center of gravity towards deep R&D: cell therapies, engineered T‑cell platforms, cancer vaccines, and autoimmune treatments. These are cutting‑edge, highly complex areas that demand heavy, long‑term investment, strong scientific talent, and strict regulatory work. At this stage, the biotech pipeline appears more aspirational than proven, so the innovation story is rich in potential but very high in uncertainty.

Summary

HKPD is in the middle of a major identity shift—from a small, tech‑enabled pharma logistics provider into a biotech company with ambitions in advanced cell therapies. The financial statements show a tiny, early‑stage profile, with little revenue, minimal assets, and no meaningful cash‑flow history, which means the numbers do not yet validate either the logistics business or the future biotech plans. Operationally, the company does have a real niche in cross‑border pharma e‑commerce and some digital process strengths, but moving into biotechnology is a completely different game, with new risks, capital needs, and execution challenges. The long‑term story will depend far more on the success of building and funding a credible R&D engine—clinical results, approvals, and partnerships—than on past logistics performance. Overall, this is best viewed as a transformation story with substantial promise on paper but also considerable strategic, scientific, and financial uncertainty.